Literature DB >> 33471148

Patients 80 + have similar medication initiation rates to those aged 50-79 in Ontario FLS.

J E M Sale1,2, A Yang3, V Elliot-Gibson3, R Jain4, R Sujic3, D Linton3, J Weldon4, L Frankel3, E Bogoch5.   

Abstract

Among individuals presenting to an Ontario FLS, we compared bone active medication initiation rates of patients 80 years and older with those 50-79 years old. After accounting for fracture risk status, there was no statistically significant difference in medication initiation rates between the two age groups
INTRODUCTION: A Fracture Liaison Service (FLS) offers post-fracture services to individuals over the age of 50 years and could potentially address age inequities in pharmacotherapy often observed for older adults. Among individuals presenting to an Ontario FLS and classified as being at high risk for future fracture, our objective was to compare bone active medication initiation rates of patients 80 years and older with those 50-79 years old.
METHODS: In 39 FLS fracture clinics across Ontario, Canada, fracture prevention coordinators identified, assessed, and facilitated the referral of eligible patients for bone densitometry, fracture risk assessment, and implementation of pharmacotherapy in patients classified as high risk for future fracture. Variables assessed at baseline included age, sex, marital status, living location, fracture location, history of previous fracture, parent's history of hip fracture, history of falls, and fracture risk status. At 6 months, bone active medication initiation was assessed in patients classified as high risk for future fracture. The Chi-square test of independence was used to compare medication initiation rates between patients 80 + and those 50-79 years old.
RESULTS: Our sample size consisted of 808 patients aged 50-79 years and 346 aged 80 + years. After accounting for fracture risk status, there was no statistically significant difference in medication initiation rates of patients 50-79 and 80 + years old (76.9% versus 73.7%, p = 0.251).
CONCLUSION: A systematic approach to identifying patients at high risk for future fracture and tailoring treatment recommendations to these patients appeared to eliminate differences in treatment initiation rates based on older age.

Entities:  

Keywords:  Fracture liaison service; Fracture risk; Fragility fracture; Medication initiation

Year:  2021        PMID: 33471148     DOI: 10.1007/s00198-020-05796-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  31 in total

1.  Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.

Authors:  Mickaël Hiligsmann; Jean-Yves Reginster
Journal:  Bone       Date:  2010-03-18       Impact factor: 4.398

Review 2.  Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis.

Authors:  K Ganda; M Puech; J S Chen; R Speerin; J Bleasel; J R Center; J A Eisman; L March; M J Seibel
Journal:  Osteoporos Int       Date:  2012-07-25       Impact factor: 4.507

3.  Age discrimination in osteoporosis screening--data from the Aalborg University Hospital Record for Osteoporosis Risk Assessment (AURORA).

Authors:  Stig Andersen; Peter Laurberg
Journal:  Maturitas       Date:  2014-01-09       Impact factor: 4.342

Review 4.  Quality Improvement Initiatives in Fragility Fracture Care and Prevention.

Authors:  Paul J Mitchell; Cyrus Cooper; Masaki Fujita; Philippe Halbout; Kristina Åkesson; Matthew Costa; Karsten E Dreinhöfer; David R Marsh; Joon-Kiong Lee; Ding-Cheng Derrick Chan; M Kassim Javaid
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

5.  The fracture and osteoporosis clinic: 1-year results and 3-month compliance.

Authors:  Marion C Blonk; Ronald J Erdtsieck; Marian G A Wernekinck; Erik J Schoon
Journal:  Bone       Date:  2007-03-01       Impact factor: 4.398

6.  Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women.

Authors:  M Hiligsmann; O Bruyère; J-Y Reginster
Journal:  Osteoporos Int       Date:  2009-04-07       Impact factor: 4.507

7.  Long-term persistence with anti-osteoporosis drugs after fracture.

Authors:  C Klop; P M J Welsing; P J M Elders; J A Overbeek; P C Souverein; A M Burden; H A W van Onzenoort; H G M Leufkens; J W J Bijlsma; F de Vries
Journal:  Osteoporos Int       Date:  2015-03-31       Impact factor: 4.507

8.  Effectiveness of a minimal resource fracture liaison service.

Authors:  K F Axelsson; R Jacobsson; D Lund; M Lorentzon
Journal:  Osteoporos Int       Date:  2016-05-26       Impact factor: 4.507

9.  Risk of imminent fracture following a previous fracture in a Swedish database study.

Authors:  J Banefelt; K E Åkesson; A Spångéus; O Ljunggren; L Karlsson; O Ström; G Ortsäter; C Libanati; E Toth
Journal:  Osteoporos Int       Date:  2019-01-24       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.